Fig. 4: Antiviral effect of CIPS against SARS-CoV-2 VOCs. | Nature Nanotechnology

Fig. 4: Antiviral effect of CIPS against SARS-CoV-2 VOCs.

From: A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination

Fig. 4: Antiviral effect of CIPS against SARS-CoV-2 VOCs.

a, Representative configurations and adsorption interfaces of the wild-type (WT) and mutant RBDs. The mutated residues in the VOC RBDs are shown in green. The residues at the binding interface with CIPS are shown in blue. b,c, Interaction energy between the RBDs and CIPS (b) and the number of contact atoms (c) in the RBD when approaching the CIPS surface. d, Binding affinity between CIPS and the mutant RBDs of SARS-CoV-2 VOCs, measured by BLI. CIPS was immobilized on the BLI sensor and immersed in mutant RBD solutions. e, CIPS inhibits the in vitro infectivity of SARS-CoV-2 VOCs. The antiviral effect of CIPS was measured on Vero-E6 cells 48 h after infection by SARS-CoV-2 VOCs in the absence or presence of CIPS. SARS-CoV-2 ORF1ab was quantitatively evaluated by real-time PCR (rtPCR). Mean Âħ s.e.m. of n = 3 biological replicates. Statistical significance was calculated by one-way ANOVA with Tukey’s multiple comparisons test.

Source data

Back to article page